JP2020502130A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502130A5
JP2020502130A5 JP2019531797A JP2019531797A JP2020502130A5 JP 2020502130 A5 JP2020502130 A5 JP 2020502130A5 JP 2019531797 A JP2019531797 A JP 2019531797A JP 2019531797 A JP2019531797 A JP 2019531797A JP 2020502130 A5 JP2020502130 A5 JP 2020502130A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
conjugate
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531797A
Other languages
English (en)
Japanese (ja)
Other versions
JP7162592B2 (ja
JP2020502130A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/065995 external-priority patent/WO2018111989A1/en
Publication of JP2020502130A publication Critical patent/JP2020502130A/ja
Publication of JP2020502130A5 publication Critical patent/JP2020502130A5/ja
Application granted granted Critical
Publication of JP7162592B2 publication Critical patent/JP7162592B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531797A 2016-12-14 2017-12-13 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療 Active JP7162592B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662434380P 2016-12-14 2016-12-14
US62/434,380 2016-12-14
US201762575050P 2017-10-20 2017-10-20
US62/575,050 2017-10-20
PCT/US2017/065995 WO2018111989A1 (en) 2016-12-14 2017-12-13 Fibroblast activation protein (fap)-targeted imaging and therapy

Publications (3)

Publication Number Publication Date
JP2020502130A JP2020502130A (ja) 2020-01-23
JP2020502130A5 true JP2020502130A5 (https=) 2021-01-28
JP7162592B2 JP7162592B2 (ja) 2022-10-28

Family

ID=62559225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531797A Active JP7162592B2 (ja) 2016-12-14 2017-12-13 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療

Country Status (6)

Country Link
US (4) US20200237936A1 (https=)
EP (1) EP3555627B1 (https=)
JP (1) JP7162592B2 (https=)
CN (2) CN116474108A (https=)
ES (1) ES2972577T3 (https=)
WO (1) WO2018111989A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
US11780821B2 (en) 2017-12-15 2023-10-10 Praxis Biotech LLC Inhibitors of fibroblast activation protein
EP3749663A1 (en) * 2018-02-06 2020-12-16 Universität Heidelberg Fap inhibitor
WO2019154859A1 (en) * 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
CN112543651B (zh) * 2018-08-07 2023-06-02 普渡研究基金会 使car t细胞恢复活力
US11426472B2 (en) 2018-10-17 2022-08-30 Purdue Research Foundation Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
US11504364B2 (en) 2018-12-21 2022-11-22 Praxis Biotech LLC Inhibitors of fibroblast activation protein
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use
CN114901315B (zh) * 2019-09-17 2025-04-29 普渡研究基金会 癌症和其他纤维化和炎性疾病的成纤维细胞活化蛋白(fap)靶向的成像和治疗
EP4096677A4 (en) * 2020-01-31 2024-02-28 Purdue Research Foundation Fibroblast activation protein (fap) - targeted antifibrotic therapy
EP4019507A1 (en) 2020-02-12 2022-06-29 Philochem AG Fibroblast activation protein ligands for targeted delivery applications
EP4126053A4 (en) * 2020-03-24 2024-11-20 Trustees Of Tufts College IMAGING AGENTS AND RADIOPHARMACEUTICALS TARGETING FAP, AND USES THEREOF
WO2021207682A2 (en) * 2020-04-09 2021-10-14 Philip Stewart Low Pi3 kinase inhibitors and uses thereof
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
US20220211883A1 (en) * 2020-12-17 2022-07-07 Trustees Of Tufts College Fap-activated radiotheranostics and uses related thereto
CN114790195B (zh) * 2020-12-21 2024-05-17 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
EP4043452A1 (en) 2021-02-12 2022-08-17 Philochem AG Bivalent fibroblast activation protein ligands for targeted delivery applications
CA3207999A1 (en) * 2021-02-12 2022-08-18 Samuele CAZZAMALLI Bivalent fibroblast activation protein ligands for targeted delivery applications
JP2024510267A (ja) * 2021-03-16 2024-03-06 パーデュー・リサーチ・ファウンデーション 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
TW202304469A (zh) * 2021-03-24 2023-02-01 美商杜夫特學院信託管理公司 酸化合物、組合物及方法
US12599683B2 (en) * 2021-05-19 2026-04-14 Ferronova Pty Ltd Mapping nanoparticles
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
CN113521313A (zh) * 2021-07-22 2021-10-22 戴格普瑞生物科技(苏州)有限公司 靶向造影剂、产品、制备方法及应用
CN117460826A (zh) * 2021-09-14 2024-01-26 菲柏生物医学技术(广州)有限公司 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用
KR20240093543A (ko) 2021-10-04 2024-06-24 필로켐 아게 방사성 표지된 섬유모세포 활성화 단백질 리간드
KR20240109256A (ko) * 2021-11-03 2024-07-10 애드센트릭스 테라퓨틱스 잉크. 약물 접합체 및 이의 제조 및 사용 방법
US20250177582A1 (en) 2022-01-30 2025-06-05 Philochem Ag High-affinity ligands of fibroblast activation protein for targeted delivery applications
CN114214061B (zh) * 2022-02-22 2022-05-17 北京大学 一种聚乙二醇修饰的两性离子化荧光探针、制剂及其应用
CA3266566A1 (en) 2022-09-06 2024-03-14 Philochem Ag MULTIVALENT FIBROBLAST ACTIVATING PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
KR20250073273A (ko) 2022-09-23 2025-05-27 누클리디움 아게 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
WO2024102956A1 (en) * 2022-11-09 2024-05-16 Purdue Research Foundation Keto-amide-based fibroblast activation protein-targeted ligand linked to an imaging or therapeutic agent, compositions and methods of use
CN120957982A (zh) * 2023-05-08 2025-11-14 江苏恒瑞医药股份有限公司 靶向成纤维细胞活化蛋白的配体
CN116621823B (zh) * 2023-07-06 2023-10-31 南京诺源医疗器械有限公司 诊断转移淋巴结近红外荧光示踪剂、合成方法及应用
WO2025046043A1 (en) 2023-08-31 2025-03-06 Stichting Radboud Universitair Medisch Centrum Endometriosis tracer

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767242A (en) 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5851775A (en) 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
US20020004490A1 (en) 1999-04-12 2002-01-10 Dean Nicholas M. Antisense modulation of Fas mediated signaling
WO1999047152A2 (en) 1998-03-20 1999-09-23 Sloan Kettering Institute For Cancer Research Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
GB9827430D0 (en) 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
US20090010919A1 (en) 2004-07-29 2009-01-08 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap)
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
EP1812458A2 (en) 2004-10-27 2007-08-01 Wen-Tien Chen Methods and compositions for seprase inactivation
US7399869B2 (en) 2005-05-19 2008-07-15 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US7998997B2 (en) 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
US8067248B2 (en) 2005-12-14 2011-11-29 Luwig Institute for Cancer Research Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
US20100047170A1 (en) 2006-01-05 2010-02-25 Denmeade Samuel R Peptide Prodrugs
AU2007258495A1 (en) 2006-06-07 2007-12-21 Victoria J. Christiansen Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
PT2035581E (pt) 2006-06-21 2012-12-06 Scripps Research Inst Composição de adn contra o antigénio do estroma tumoral fap e métodos de utilização desta
ATE472602T1 (de) 2006-07-25 2010-07-15 Pasteur Institut Rekombinanter mycobakteriumstamm, der ein fap protein aus mycobakterium unter der kontrolle eines promotors, der unter hypoxischen konditionen aktiv ist, exprimiert, und dessen verwendung zur tumortherapie
AU2007289168A1 (en) 2006-08-29 2008-03-06 Molecular Insight Pharmaceuticals, Inc. Radioimaging moieties coupled to peptidase-binding moieties for imaging tissues and organs that express peptidases
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
WO2008116053A2 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2009024542A2 (en) 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
CN101896818B (zh) 2007-12-10 2016-01-20 霍夫曼-拉罗奇有限公司 作为癌症的标记物的Seprase
JP2011523551A (ja) 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
CA3162577C (en) * 2008-05-20 2023-09-26 University Health Network Device and method for fluorescence-based imaging and monitoring
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2010083570A1 (en) 2009-01-23 2010-07-29 The University Of Sydney Novel metabolic disease therapy
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
CA2807244A1 (en) 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
PL2753334T3 (pl) 2011-08-30 2022-12-12 Trustees Of Tufts College Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
WO2013107820A1 (en) * 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
EP2844246A4 (en) 2012-05-04 2016-02-24 Univ Oklahoma SUBSTRATES AND PROCLOSURES OF PROLYLOLIGOPEPTIDASE AND FIBROBLAST ATTACHMENT PROTEIN AND METHOD OF USE
US20150320892A1 (en) 2012-06-29 2015-11-12 Ge Healthcare Limited Imaging fibrosis
WO2014022636A1 (en) 2012-08-02 2014-02-06 Trustees Of Tufts College Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
CA2891028C (en) 2012-11-09 2017-02-07 F. Hoffmann-La Roche Ag In vitro capture and analysis of circulating tumor cells
US9402888B2 (en) 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
WO2014149069A1 (en) 2013-03-15 2014-09-25 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014167083A1 (en) 2013-04-12 2014-10-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
CN103267852B (zh) 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
GB2538023A (en) 2014-02-03 2016-11-02 Philochem Ag Targeted drug conjugates
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN106573073B (zh) 2014-06-13 2021-09-28 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
JP6810687B2 (ja) 2014-10-08 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Fap及びdr5に特異的な二重特異性抗体と化学療法剤との併用療法
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
CA2973040A1 (en) 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20160303251A1 (en) * 2015-04-17 2016-10-20 Endocyte, Inc. Conjugates of garftase inhibitors
RS65188B1 (sr) 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
CN106046121B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
CN105949282B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
CN116474108A (zh) * 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EP3606939A4 (en) 2017-04-04 2021-01-20 F. Hoffmann-La Roche AG SUBSTRATES RECOGNIZED BY FIBROBLAST ACTIVATION PROTEIN (FAP) AND METHOD OF USING THEM
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
CN109796532B (zh) 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用
CN108152258A (zh) 2017-12-13 2018-06-12 清华大学 一种检测待测溶液中氨基糖苷类抗生素的含量的方法
US11780821B2 (en) 2017-12-15 2023-10-10 Praxis Biotech LLC Inhibitors of fibroblast activation protein
CN108333365B (zh) 2018-01-24 2020-09-04 南开大学 金-长余辉纳米粒子免原位激发检测成纤维细胞激活蛋白
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
US11426472B2 (en) 2018-10-17 2022-08-30 Purdue Research Foundation Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
JP2022516555A (ja) 2019-01-04 2022-02-28 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
CN110368496B (zh) 2019-07-11 2020-12-29 同济大学 成纤维细胞激活蛋白抑制剂在制备药物中的用途
CN111574634B (zh) 2019-12-16 2022-04-19 四川大学华西医院 同时靶向间皮素和fap的双靶点嵌合抗原受体及其用途
CN111235221B (zh) 2020-01-22 2022-08-05 北京大学第一医院 一种fap抑制剂的活性检测方法

Similar Documents

Publication Publication Date Title
JP2020502130A5 (https=)
AU2016358441B2 (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
CN110291401B (zh) 成纤维细胞活化蛋白(fap)-靶向成像和治疗
CN105102003B (zh) 吡咯并苯并二氮杂卓-抗psma抗体结合物
CN105102068B (zh) 吡咯并苯并二氮杂卓-抗体结合物
CN105102004B (zh) 吡咯并苯并二氮杂卓-抗cd22抗体结合物
CN105050661B (zh) 吡咯并苯并二氮杂卓‑抗体结合物
JP2020502131A5 (https=)
CN107057398B (zh) 一种七甲川菁荧光染料及其肿瘤精准诊断和治疗的应用
RU2003137593A (ru) Соединения на основе пептидов для направленной доставки к рецепторам интегринов
CN104955485A (zh) 吡咯并苯并二氮杂卓-抗her2抗体结合物
JP7184775B2 (ja) 黄体化ホルモン放出ホルモン受容体(lhrh-r)コンジュゲートおよびその使用
CA3104821C (en) Photodynamic compositions and methods of use
CN111372609A (zh) 声动力学疗法
JP2020109099A (ja) 蛍光イメージングのためのir色素
CN109922834B (zh) 用于治疗癌症的卟啉化合物和组合物
JP2019515880A5 (https=)
JP2018512390A (ja) Psmaリガンド−チューブリシン化合物を用いた癌の処置方法
CN114945374A (zh) 药物组合物和方法
JPWO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
US20210079039A1 (en) Compositions and methods for the selective delivery of therapeutic and imaging agents
US20220347306A1 (en) Selective delivery of therapeutic and imaging agents
JP2024518097A (ja) 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法
Wang et al. A Near-Infrared Fluorogenic Spray Probe for Rapid and Wash-Free Intraoperative Nerve Imaging
CA3006018C (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy